SoftBank will exit social video app developer Hyperconnect roughly six years after it took part in an $8.6m series A round.

The share price of Columbia University's cellular oncology drug developer, backed by Osage University Partners, has doubled since it floated.

The share price of the cellular oncology drug developer, which counts Novartis, Johnson & Johnson and PureTech Health as investors, has doubled since it floated.

The Eli Lilly-backed liver disease drug developer floated at the top of its range to raise almost $128m, following $207m of venture funding.

Eli Lilly and WuXi AppTec scored exits from the immunotherapy developer, which has seen its shares rocket 66% since it floated.

The Novo, Pfizer and Nan Fung-backed oncology therapy developer priced an upsized offering above its range and is now valued above $1bn.

Alphabet and Ping An are in line for exits after the online health insurer filed to float on the New York Stock Exchange.

SoftBank's Vision Fund is reportedly urging some of its larger portfolio companies to seek initial public offerings during a bull market.

Stanford spinout Bolt Biotherapeutics has raised more than twice as much as originally planned in an offering that also provided exits for corporates Pfizer, Novo and Fan Fung.

Immunocore has raised more than $258m in an upsized offering and an additional $15m in a concurrent private placement.